Literature DB >> 2805354

IgA isotyping of antigliadin antibodies. A possible clue for a less invasive diagnosis of coeliac disease.

A Elewaut1, G Dacremont, E Robberecht, J Leroy, M H De Baets.   

Abstract

An enzyme-linked immunosorbent assay was used to measure serum antigliadin antibodies (AGA) of IgG and IgA classes. The assay was modified to measure IgA1 and IgA2 subclasses with monoclonal anti-IgA subclass antibodies. Serum IgG- and IgA-AGA levels were elevated in patients with coeliac disease (CD) but an overlap was seen with control sera. IgA-AGA isotyping using monoclonal anti-human IgA1 and IgA2 antibodies increased the sensitivity and specificity of the assay to almost 100%. All patients with active untreated CD and none of the control groups had elevated IgA1-AGA and IgA2-AGA. In order to measure the relative distribution of IgA1-AGA versus IgA2-AGA an IgA1/IgA2 ratio was calculated. In patients with active untreated CD a ratio of 2.8 was found, declining to 2.2 during treatment. A gluten challenge increased the ratio to 3.4. These findings suggest that IgA1-AGA subclass measurements are a useful screening test before small bowel biopsies are performed. This method can also be used to assess the results of a gluten free diet.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805354     DOI: 10.1016/0009-8981(89)90362-8

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Endomysial antibody: is it the best screening test for coeliac disease?

Authors:  M Ferreira; S L Davies; M Butler; D Scott; M Clark; P Kumar
Journal:  Gut       Date:  1992-12       Impact factor: 23.059

2.  Predictive value for coeliac disease of antibodies to gliadin, endomysium, and jejunum in patients attending for jejunal biopsy.

Authors:  S A McMillan; D J Haughton; J D Biggart; J D Edgar; K G Porter; T A McNeill
Journal:  BMJ       Date:  1991-11-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.